Engineered immune cells take aim at two cancer targets
NCT ID NCT05437328
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new treatment using a patient's own immune cells, engineered to recognize and attack cancer cells that have two specific markers (GD2 and CD56). The trial includes 60 people with advanced cancers that have not responded to standard therapy. The goal is to see if this approach is safe and effective.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- bi-4SCAR GD2/CD56 T cells
- What this could lead to
- If successful, this could offer a new treatment option for patients with certain hard-to-treat cancers that express GD2 or CD56.
- What could go wrong
- This is an early-phase trial with only 60 participants, so results may not apply broadly. CAR-T therapy can cause serious side effects like cytokine release syndrome.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shenzhen Geno-immune Medical Institute
RECRUITINGShenzhen, Guangdong, 518000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.